Document is current
Any future updates will be listed below
-
Authors
Tu, Thomas
Okeke, Sylvester
Ajoyan, Harout
Mozumder, Sumaya
Vu, Mylisa
Horwitz, Robyn
Cama, Elena
George, Jacob
Brener, Loren
-
Funding
Funding for this research was provided by:
Gilead Sciences (Investigator sponsored research, Investigator sponsored research, Investigator sponsored research, Investigator sponsored research, Investigator sponsored research)
Paul and Valeria Ainsworth (Precision Medicine Fellowship)
Robert W Storr (Bequest, Bequest)
- License Information
-
More Information
Article History
Received: 2 March 2025
Accepted: 21 June 2025
First Online: 28 June 2025
Declarations
:
: This research had ethics approval from the University of New South Wales Human Research Ethics Committee (Protocol number iRECS3711). The study was all research was carried out in accordance with the 2023 National Health and Medical Research Council’s (NHMRC) National Statement on Ethical Conduct in Human Research, as well as the Declaration of Helsinki. All participants of this study provided informed consent.
: Not applicable.
: Thomas Tu serves as consultant to Excision BioTherapeutics and Kerna Ventures with fees to his institution, as paid consultant to Gilead Sciences and GSK, and received payment for speaking engagements from GSK, ASHM, and the Singapore HBV Cure conference. All other authors declare no relevant conflicts of interest.
